-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 27, the CDE official website showed that a number of Class 1 new drug clinical trial applications were approved by the China Food and Drug Administration.
SHR-1819 injection targets IL-4R, which can block the interleukin pathway, inhibit the transmission of downstream inflammatory signals, and ultimately improve the inflammatory state of the disease and control the progression of the disease
MIL62 is a new generation of type II CD20 antibody, which is optimized by Tianguangshi's independent innovation of glycosylated antibody technology platform
Finasteride spray and LPM3770164 sustained-release tablets were both approved for clinical use for the first time